BioXcel Therapeutics is trading at $0.14 (+30.00%) after continued volatility surrounding its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to Teva.
- Teva’s stalking-horse agreement includes $57.5 million upfront, potential milestone payments, and a court-supervised sale process.
- The transaction remains subject to higher bids and court approval.
- No separate September 3, 2026 announcement was identified; the move appears linked to ongoing bankruptcy-sale developments.